Autoinflammatory & rare systemic diseases
Sensorineural hearing loss in anti-interleukin-1 treated Cryopyrin-Associated Periodic Syndromes (CAPS) patients: risk factors and real-life barriers—an observational study
Authors' conclusion
Early diagnosis, timely intervention and a refined Treat-to-Target approach are vital for hearing in lifelong CAPS management.
Study context
- Population
- Consecutive paediatric and adult anti-IL-1-treated CAPS patients with sensorineural hearing loss, 2006–202420 males · 16 females
- Participants
- 36 participants
- Outcome
- WHO grade of hearing impairment
- Follow-up
- Last
Methodological detailssingle-centre, observational, consecutive patients
- Single-centre
- Observational
- Consecutive patients
Main finding
As reported in the abstract
WHO grade of hearing impairment at last follow-up
Hearing loss present at last follow-up
88%
Observational data: associations, not effects.
Further findings
Hearing loss at baseline
- Hearing loss present
- 83%
- HF-PTA sensitivity
- 100%
Therapy escalation due to progressive hearing loss
- Patients requiring escalation
- 10
- Of whom carried pathogenic mutations
- 8
- Early progression primarily driven by disease activity; late progression predominantly by non-compliance
Hearing course over time
- Stable hearing
- 86%
- Improvement
- 8%
- Worsening
- 6%
Original publication
Sensorineural hearing loss in anti-interleukin-1 treated CAPS patients: risk factors and real-life barriers—an observational study. Rheumatology (Oxford). Published 1 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →